Developer docs
API playgroundTry for free, no card

Search company profiles

Persistence Capital Partners

Full company profile

uuid0002eqw

Namestring
Persistence Capital Partners
Legal namestring
PCP GP Inc.
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Persistence Capital Partners is a Canadian private equity firm that invests exclusively in the Canadian healthcare sector. Founded in 2008 by Dr. Sheldon Elman and Stuart M. Elman, the firm is headquartered in Montreal (Westmount) with an additional office in Toronto and operates with a lean team of 8 investment professionals. Its investment thesis is narrowly focused on mid-market Canadian healthcare businesses, and over 17 years it has built a track record of 4 active portfolio companies alongside 17+ completed exits.

The firm's portfolio spans a diverse set of healthcare sub-sectors, including medical imaging, laboratory services, occupational health, diabetes care, fertility services, dental, pharmacy, veterinary, clinical research, and medical aesthetics. Active holdings include Anova, Neighbourly Pharmacy, LMC Healthcare (diabetes/endocrine), and MedSpa Partners; historically exited companies include Medisys (sold to TELUS Health, 2018), EnvironeX (sold to Eurofins, 2018), and Neighbourly Pharmacy itself, which was taken public on the Toronto Stock Exchange in 2021 raising approximately CAD 175 million. The most recent realization is the sale of MCA Dental Group to 123Dentist, announced in October 2025.

PCP earns revenue through traditional private equity economics: management fees (typically around 2% of committed capital) on its healthcare-focused funds, supplemented by carried interest on successful realizations. The firm has raised successive fund vintages — Fund I initiated in 2008, Fund II with a first close above CAD 90 million against a CAD 225 million target in 2013, and a third fund initiated around 2017 — providing a recurring, capital-light revenue base tied to long-duration limited-partner commitments.

Short descriptiontext

Persistence Capital Partners is a Montreal-based Canadian private equity firm founded in 2008 that invests exclusively in mid-market Canadian healthcare companies, currently managing 4 active portfolio companies and 17+ historical exits across diverse sub-sectors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMontreal, Canada
HQ citystring
Montreal
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
private equity healthcare, healthcare investments, growth capital, management buyouts, healthcare consolidation
Industry3 codes
PRIMARYFSANAAAK
Secondary Venture Funds (VC Secondaries)
SECONDARYFSANAFAB
GP-led Continuation Funds (Single-Asset & Multi-Asset)
Financial & Insurance/Private Equity & Venture Capital/Secondaries Funds (LP Stakes & GP-led)
SECONDARYFSANAFAK
Tail-End / Residual Portfolio Secondaries
Financial & Insurance/Private Equity & Venture Capital/Secondaries Funds (LP Stakes & GP-led)
NAICS code2 codes
  • Portfolio Management and Investment Advice523940
  • Other Investment Pools and Funds5259
SIC code1 code
  • Investment Advice6282
Product category
Private Equity Healthcare
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Private equity fund management
TypeManaged Services
Description

PCP raises and manages private equity funds (Fund I initiated 2008, Fund II first closing raised $90M+ in 2013 with $225M target, Fund III active since 2019) investing exclusively in Canadian healthcare. Revenue is generated from management fees charged to limited partners, carried interest/performance fees on successful exits, and direct returns from equity investments in portfolio companies. Limited Partners include leading Canadian institutional investors, Canadian financial institutions, and high net worth individuals.

persistencecapital.com
2Strategic advisory and transaction support
TypeProfessional Services
Description

PCP provides ongoing strategic direction, transaction support, board representation, and operational guidance to portfolio companies across mergers and acquisitions, recapitalizations, divestitures/carve-outs, distressed financing, and restructuring engagements.

persistencecapital.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Persistence Capital Partners is a Canadian private equity firm that raises and manages limited partnership funds (Fund I initiated 2008, Fund II first closed 2013, Fund III active since 2019) investing exclusively in Canadian healthcare businesses. PCP acquires private companies, supports management buy-outs, provides growth capital, and leads industry consolidations and roll-ups. The firm also provides ongoing strategic direction, board representation, and transaction support (M&A, recapitalizations, divestitures, distressed financing, and restructuring) to its portfolio companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 30+ years investing in, running, and growing healthcare businesses in Canada
+6 more records
Product and service4 records
1Persistence Capital Partners Fund I (PPC I / Partenaires Persistance Capital S.E.C.)
CategoryPrivate Equity Fund
Description

First PCP private equity fund, initiated in 2008 at the time of the firm's founding, providing capital for investments in Canadian healthcare businesses, growth equity, buy-outs, and industry consolidations. Limited partners include leading Canadian institutional investors, Canadian financial institutions, and high net worth individuals.

2Persistence Capital Partners Fund II (PPC II / Partenaires Persistance Capital II s.e.c.)
CategoryPrivate Equity Fund
Description

Second PCP private equity fund with a first close of more than CAD 90 million completed in May 2013 and a target fund size of CAD 225 million. Invests in growth capital, management buy-outs, industry consolidation, recapitalizations, and refinancings of Canadian healthcare businesses with CAD 5-50 million in revenue. The vast majority of Fund I limited partners returned for Fund II.

3Persistence Capital Partners Fund III (PCP Fund III)
CategoryPrivate Equity Fund
Description

Third PCP private equity fund, active since 2019, continuing PCP's healthcare-focused investment strategy in Canada. Limited partners include Canadian institutional investors and other limited partners; specific fund size not disclosed in the input.

4Strategic advisory and transaction support services
CategoryInvestment Advisory Services
Description

Ongoing strategic direction, transaction support, board representation, and operational guidance provided to PCP portfolio companies across mergers and acquisitions, recapitalizations, divestitures/carve-outs, distressed financing, and restructuring engagements. Provided to portfolio companies alongside fund investment.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1Steve Organ
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-04-14
Description

Founder of Summit Veterinary Pharmacy (1998), Canada's largest veterinary compounding pharmacy. PCP's investment in April 2020 (4th investment in Fund III) supports Summit's growth as an Ontario-accredited pharmacy serving veterinarians across Canada.

persistencecapital.com
2Dominic Mazzone
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-12-05
Description

Serial entrepreneur who co-founded MedSpa Partners Inc. (MSP) with PCP in December 2019. As CEO of MSP, Mazzone leads the acquisition platform consolidating Canada's premier medspas and cosmetic dermatology clinics, supported by PCP as principal investor.

persistencecapital.com
3Dr. Mark Lupin
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-12-05
Description

Dermatologist and Founding Partner of MedSpa Partners, joining from Cosmedica (Victoria, BC). Dr. Lupin helps shape the unique partnership model that attracts leading Canadian medical aesthetics practitioners to MSP's platform.

persistencecapital.com
4Ken Craig and Dr. Mark McCullough (MCA Dental Group)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-09-04
Description

Founders of Groupe Dentaire MCA (2017), a dental services organization partnering with Canadian dentists. PCP made its initial investment in early 2018 and a follow-on investment in September 2019 to accelerate MCA's growth. In 2025, 123Dentist (backed by Peloton Capital) announced the acquisition of MCA Dental Group.

persistencecapital.com
5Dr. Marjorie Dixon
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-06-27
Description

Founder, Medical Director and CEO of Anova Fertility & Reproductive Health. PCP partnered with Dr. Dixon in June 2019 to provide growth capital for new clinic openings, technology investment, and physician recruitment. Anova operates Canada's first next-generation embryology laboratory.

persistencecapital.com
6Marc Hamilton
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

Founder of EnvironeX (2005) and registered microbiologist with 20+ years of experience. PCP invested in EnvironeX in 2015 and supported its growth to 275+ employees and ~$30M CAD revenue before selling to Eurofins in October 2018.

persistencecapital.com
7Dr. Ronnie Aronson
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2014-11-10
Description

Founder of LMC Diabetes & Endocrinology (1997) and one of Canada's leading endocrinologists. PCP's first portfolio company investment in November 2014 supported LMC's national growth strategy. LMC has grown to 30+ endocrinologists across 9 clinics in Ontario, Alberta, and Quebec, and was consistently recognized among Canada's Best Workplaces.

persistencecapital.com
Recent move15 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Quebec-headquartered Canadian private equity firm with a dedicated healthcare vertical and mid-market focus. Highly comparable as a Montreal/Toronto-based competitor sourcing Canadian healthcare buyouts and growth capital deals in similar revenue ranges.

TypeBroad incumbent
Description

Large US private equity firm with a long-standing dedicated healthcare practice. Comparable as an established healthcare-focused investor, though substantially larger fund size and US-centric deployment.

TypeBroad incumbent
Description

Larger North American private equity firm operating across multiple sectors including healthcare. Comparable as a mid-market PE investor with operational value-creation focus, though broader sector mandate differs from PCP's healthcare-only thesis.

TypeDirect peer
Description

US-based healthcare-dedicated private equity firm. Comparable as a healthcare-only PE specialist focused on mid-to-large healthcare services and pharma services businesses.

TypeDirect peer
Description

US-based healthcare-exclusive private equity firm. Comparable as a healthcare-only mid-market PE specialist, though operating primarily in the US rather than Canada.

TypeDirect peer
Description

Toronto-based Canadian mid-market private equity firm with significant healthcare exposure. Most directly comparable as a Canadian-domiciled PE sponsor competing for similar mid-market healthcare transactions and management buyouts.

TypeDirect peer
Description

Canadian mid-market private equity firm investing across business services, consumer, and healthcare. Comparable as a Toronto-based sponsor competing for mid-market Canadian healthcare buyouts, growth capital, and management buyouts.

TypeDirect peer
Description

Canadian mid-market private equity firm with active healthcare/dental vertical (notably the acquirer of PCP's MCA Dental Group). Comparable as a competing Canadian PE sponsor in healthcare services platforms and consolidations.

TypeBroad incumbent
Description

Large Canadian-headquartered private equity platform with healthcare investments. Comparable as a Canadian PE competitor for larger healthcare transactions, though broader mandate and significantly larger fund size differ from PCP's mid-market focus.

10Imperial Capital Group
TypeRegional player
Description

Canadian private equity investment firm with focus on mid-market healthcare and growth services. Comparable as a competing Canadian mid-market PE investor in similar healthcare verticals.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers12 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries20 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment21 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Persistence Capital Partners

Private Equity Healthcarepersistencecapital.com

Persistence Capital Partners is a Montreal-based Canadian private equity firm founded in 2008 that invests exclusively in mid-market Canadian healthcare companies, currently managing 4 active portfolio companies and 17+ historical exits across diverse sub-sectors.

What Persistence Capital Partners does

Persistence Capital Partners is a Canadian private equity firm that invests exclusively in the Canadian healthcare sector. Founded in 2008 by Dr. Sheldon Elman and Stuart M. Elman, the firm is headquartered in Montreal (Westmount) with an additional office in Toronto and operates with a lean team of 8 investment professionals. Its investment thesis is narrowly focused on mid-market Canadian healthcare businesses, and over 17 years it has built a track record of 4 active portfolio companies alongside 17+ completed exits.

The firm's portfolio spans a diverse set of healthcare sub-sectors, including medical imaging, laboratory services, occupational health, diabetes care, fertility services, dental, pharmacy, veterinary, clinical research, and medical aesthetics. Active holdings include Anova, Neighbourly Pharmacy, LMC Healthcare (diabetes/endocrine), and MedSpa Partners; historically exited companies include Medisys (sold to TELUS Health, 2018), EnvironeX (sold to Eurofins, 2018), and Neighbourly Pharmacy itself, which was taken public on the Toronto Stock Exchange in 2021 raising approximately CAD 175 million. The most recent realization is the sale of MCA Dental Group to 123Dentist, announced in October 2025.

PCP earns revenue through traditional private equity economics: management fees (typically around 2% of committed capital) on its healthcare-focused funds, supplemented by carried interest on successful realizations. The firm has raised successive fund vintages — Fund I initiated in 2008, Fund II with a first close above CAD 90 million against a CAD 225 million target in 2013, and a third fund initiated around 2017 — providing a recurring, capital-light revenue base tied to long-duration limited-partner commitments.

Persistence Capital Partners firmographics

Firmographics
Name
Persistence Capital Partners
Legal name
PCP GP Inc.
Website
https://persistencecapital.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
Persistence Capital Partners is a Montreal-based Canadian private equity firm founded in 2008 that invests exclusively in mid-market Canadian healthcare companies, currently managing 4 active portfolio companies and 17+ historical exits across diverse sub-sectors.
Ownership category
akta.pro rank

Persistence Capital Partners industry classification

Industry
Product category
Private Equity Healthcare
NAICS
Portfolio Management and Investment Advice (523940), Other Investment Pools and Funds (5259)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAK
Secondary Venture Funds (VC Secondaries)
SECONDARYFSANAFAB
GP-led Continuation Funds (Single-Asset & Multi-Asset)
Financial & Insurance/Private Equity & Venture Capital/Secondaries Funds (LP Stakes & GP-led)
SECONDARYFSANAFAK
Tail-End / Residual Portfolio Secondaries
Financial & Insurance/Private Equity & Venture Capital/Secondaries Funds (LP Stakes & GP-led)

Keywords

  • Private equity healthcare
  • Healthcare investments
  • Growth capital
  • Management buyouts
  • Healthcare consolidation

Where Persistence Capital Partners is headquartered

Location

Headquarters

HQ city
Montreal
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

Persistence Capital Partners business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Private equity fund management: PCP raises and manages private equity funds (Fund I initiated 2008, Fund II first closing raised $90M+ in 2013 with $225M target, Fund III active since 2019) investing exclusively in Canadian healthcare. Revenue is generated from management fees charged to limited partners, carried interest/performance fees on successful exits, and direct returns from equity investments in portfolio companies. Limited Partners include leading Canadian institutional investors, Canadian financial institutions, and high net worth individuals.
  2. Strategic advisory and transaction support: PCP provides ongoing strategic direction, transaction support, board representation, and operational guidance to portfolio companies across mergers and acquisitions, recapitalizations, divestitures/carve-outs, distressed financing, and restructuring engagements.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Persistence Capital Partners product offering

Product offering

Core offering

Persistence Capital Partners is a Canadian private equity firm that raises and manages limited partnership funds (Fund I initiated 2008, Fund II first closed 2013, Fund III active since 2019) investing exclusively in Canadian healthcare businesses. PCP acquires private companies, supports management buy-outs, provides growth capital, and leads industry consolidations and roll-ups. The firm also provides ongoing strategic direction, board representation, and transaction support (M&A, recapitalizations, divestitures, distressed financing, and restructuring) to its portfolio companies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Persistence Capital Partners Fund I (PPC I / Partenaires Persistance Capital S.E.C.) First PCP private equity fund, initiated in 2008 at the time of the firm's founding, providing capital for investments in Canadian healthcare businesses, growth equity, buy-outs, and industry consolidations. Limited partners include leading Canadian institutional investors, Canadian financial institutions, and high net worth individuals.
  • Persistence Capital Partners Fund II (PPC II / Partenaires Persistance Capital II s.e.c.) Second PCP private equity fund with a first close of more than CAD 90 million completed in May 2013 and a target fund size of CAD 225 million. Invests in growth capital, management buy-outs, industry consolidation, recapitalizations, and refinancings of Canadian healthcare businesses with CAD 5-50 million in revenue. The vast majority of Fund I limited partners returned for Fund II.
  • Persistence Capital Partners Fund III (PCP Fund III) Third PCP private equity fund, active since 2019, continuing PCP's healthcare-focused investment strategy in Canada. Limited partners include Canadian institutional investors and other limited partners; specific fund size not disclosed in the input.
  • Strategic advisory and transaction support services Ongoing strategic direction, transaction support, board representation, and operational guidance provided to PCP portfolio companies across mergers and acquisitions, recapitalizations, divestitures/carve-outs, distressed financing, and restructuring engagements. Provided to portfolio companies alongside fund investment.

Quantifiable outcome

  • 30+ years investing in, running, and growing healthcare businesses in Canada
  • +6 more outcomes

Companies that use Persistence Capital Partners

Customer profile

Named customers12 records

Segments3 records

Ideal customer profiles4 records

Persistence Capital Partners technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Persistence Capital Partners partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core.

  • Steve OrgancoreStrategic or Co-development Partner · 14 April 2020Founder of Summit Veterinary Pharmacy (1998), Canada's largest veterinary compounding pharmacy. PCP's investment in April 2020 (4th investment in Fund III) supports Summit's growth as an Ontario-accredited pharmacy serving veterinarians across Canada.
  • Dominic MazzonecoreStrategic or Co-development Partner · 5 December 2019Serial entrepreneur who co-founded MedSpa Partners Inc. (MSP) with PCP in December 2019. As CEO of MSP, Mazzone leads the acquisition platform consolidating Canada's premier medspas and cosmetic dermatology clinics, supported by PCP as principal investor.
  • Dr. Mark LupincoreStrategic or Co-development Partner · 5 December 2019Dermatologist and Founding Partner of MedSpa Partners, joining from Cosmedica (Victoria, BC). Dr. Lupin helps shape the unique partnership model that attracts leading Canadian medical aesthetics practitioners to MSP's platform.
  • Ken Craig and Dr. Mark McCullough (MCA Dental Group)coreStrategic or Co-development Partner · 4 September 2019Founders of Groupe Dentaire MCA (2017), a dental services organization partnering with Canadian dentists. PCP made its initial investment in early 2018 and a follow-on investment in September 2019 to accelerate MCA's growth. In 2025, 123Dentist (backed by Peloton Capital) announced the acquisition of MCA Dental Group.
  • Dr. Marjorie DixoncoreStrategic or Co-development Partner · 27 June 2019Founder, Medical Director and CEO of Anova Fertility & Reproductive Health. PCP partnered with Dr. Dixon in June 2019 to provide growth capital for new clinic openings, technology investment, and physician recruitment. Anova operates Canada's first next-generation embryology laboratory.
  • Marc HamiltoncoreStrategic or Co-development Partner · 1 January 2015Founder of EnvironeX (2005) and registered microbiologist with 20+ years of experience. PCP invested in EnvironeX in 2015 and supported its growth to 275+ employees and ~$30M CAD revenue before selling to Eurofins in October 2018.
  • Dr. Ronnie AronsoncoreStrategic or Co-development Partner · 10 November 2014Founder of LMC Diabetes & Endocrinology (1997) and one of Canada's leading endocrinologists. PCP's first portfolio company investment in November 2014 supported LMC's national growth strategy. LMC has grown to 30+ endocrinologists across 9 clinics in Ontario, Alberta, and Quebec, and was consistently recognized among Canada's Best Workplaces.

Scale indicators9 records

Recent moves15 records

Expansion highlights4 records

Persistence Capital Partners competitors and assessment

Company assessment

Direct peers

  • Novacap: Quebec-headquartered Canadian private equity firm with a dedicated healthcare vertical and mid-market focus. Highly comparable as a Montreal/Toronto-based competitor sourcing Canadian healthcare buyouts and growth capital deals in similar revenue ranges.
  • Avista Capital Partners: US-based healthcare-dedicated private equity firm. Comparable as a healthcare-only PE specialist focused on mid-to-large healthcare services and pharma services businesses.
  • Linden Capital Partners: US-based healthcare-exclusive private equity firm. Comparable as a healthcare-only mid-market PE specialist, though operating primarily in the US rather than Canada.
  • TorQuest Partners: Toronto-based Canadian mid-market private equity firm with significant healthcare exposure. Most directly comparable as a Canadian-domiciled PE sponsor competing for similar mid-market healthcare transactions and management buyouts.
  • Birch Hill Equity Partners: Canadian mid-market private equity firm investing across business services, consumer, and healthcare. Comparable as a Toronto-based sponsor competing for mid-market Canadian healthcare buyouts, growth capital, and management buyouts.
  • Peloton Capital Management: Canadian mid-market private equity firm with active healthcare/dental vertical (notably the acquirer of PCP's MCA Dental Group). Comparable as a competing Canadian PE sponsor in healthcare services platforms and consolidations.

Broad incumbents

  • Welsh, Carson, Anderson & Stowe: Large US private equity firm with a long-standing dedicated healthcare practice. Comparable as an established healthcare-focused investor, though substantially larger fund size and US-centric deployment.
  • Wynnchurch Capital: Larger North American private equity firm operating across multiple sectors including healthcare. Comparable as a mid-market PE investor with operational value-creation focus, though broader sector mandate differs from PCP's healthcare-only thesis.
  • Onex Partners: Large Canadian-headquartered private equity platform with healthcare investments. Comparable as a Canadian PE competitor for larger healthcare transactions, though broader mandate and significantly larger fund size differ from PCP's mid-market focus.

Regional players

  • Imperial Capital Group: Canadian private equity investment firm with focus on mid-market healthcare and growth services. Comparable as a competing Canadian mid-market PE investor in similar healthcare verticals.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Persistence Capital Partners financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Persistence Capital Partners leadership team

Management profile

Number of profiles

Profiles8 records

Persistence Capital Partners subsidiaries and ownership

Company hierarchy

Subsidiaries20 records

Persistence Capital Partners funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Persistence Capital Partners M&A and investment

M&A and investment

M&A1 record

Investments21 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Persistence Capital Partners

What does Persistence Capital Partners do?

Persistence Capital Partners is a Canadian private equity firm that raises and manages limited partnership funds (Fund I initiated 2008, Fund II first closed 2013, Fund III active since 2019) investing exclusively in Canadian healthcare businesses. PCP acquires private companies, supports management buy-outs, provides growth capital, and leads industry consolidations and roll-ups. The firm also provides ongoing strategic direction, board representation, and transaction support (M&A, recapitalizations, divestitures, distressed financing, and restructuring) to its portfolio companies.

Is Persistence Capital Partners a public or private company?

Persistence Capital Partners is a private company. It is classified as management employee owned and is currently operating.

When was Persistence Capital Partners founded?

Persistence Capital Partners was founded in 2008. It employs 11 to 50 people.

Where is Persistence Capital Partners based?

Persistence Capital Partners is headquartered in Montreal, Canada, in the North America region.

How does Persistence Capital Partners make money?

Two revenue lines are on record. Private equity fund management is the primary driver. The others are strategic advisory and transaction support.

Who are Persistence Capital Partners's main competitors?

Direct peers on record are Novacap, Avista Capital Partners, Linden Capital Partners, TorQuest Partners, Birch Hill Equity Partners and Peloton Capital Management. Broad incumbents are Welsh, Carson, Anderson & Stowe, Wynnchurch Capital and Onex Partners. Imperial Capital Group is listed as a regional player.

Does Persistence Capital Partners have an API?

No public API is recorded for Persistence Capital Partners.

What industry is Persistence Capital Partners in?

Persistence Capital Partners's product category is Private Equity Healthcare. Its primary akta.pro industry code is FSANAAAK, Secondary Venture Funds (VC Secondaries), with a secondary code of FSANAFAB, GP-led Continuation Funds (Single-Asset & Multi-Asset). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Morgan StanleyPersistence Capital Partners Exceeds TargetPersistence Capital Partners closed its second investment vehicle for MedSpa Partners Inc., raising over C$375 million, which exceeded the fund's target size and more than tripled the initial investment. The capital commitment is anchored by Morgan Stanley Private Equity Secondaries and aims to strengthen MedSpa Partners' ability to acquire and grow medical aesthetics clinics in North America.NewswirePERSISTENCE CAPITAL PARTNERS ACQUIRE COMMON SHARES OF NEIGHBOURLY PHARMACY INC.Persistence Capital Partners acquired an additional 435,000 common shares of Neighbourly Pharmacy Inc. for $9.1 million, increasing its total ownership stake to approximately 50.6%. This transaction was executed as a private block trade at $21.00 per share on the Toronto Stock Exchange.GlobeNewswireNeighbourly Announces Closing of Previously Announced Public Offering and Concurrent Private PlacementNeighbourly closed its public offering of 5,175,000 subscription receipts at $28.95 each, raising about $149.8 million, and a concurrent private placement of 4,150,000 receipts to an affiliate of Persistence Capital Partners for about $120 million. The proceeds will fund the acquisition of Rubicon Pharmacies, with closing expected in the first quarter of 2023.PR NewswireMCA Dental Group Announces Significant Equity Commitment by Persistence Capital Partners and Investor Group Led by DWS's Private Equity BusinessMCA Dental Group announced a significant follow-on equity commitment from Persistence Capital Partners and an investor group led by DWS's private equity business. This capital injection supports MCA's aggressive growth strategy in Canada, aiming to expand its network of dental partners and operational support services. The investment reinforces existing backing while introducing new institutional investors to accelerate the organization's expansion targets.NewswireDr. Jane Burk-Vassallo Joins MedSpa PartnersMedSpa Partners Inc. has acquired the medical aesthetics clinic aspireMD and its lead practitioner Dr. Jane Burk-Vassallo in St. Catharines, Ontario. This expansion adds a new location to MSP's Canadian platform, leveraging the clinic's 20-year history in the Niagara region. The acquisition is supported by Persistence Capital Partners, MSP's private equity backer.GlobeNewswireZoomMed Announces the Closing of a $500,000 Financing AgreementZoomMed closed a $500,000 financing agreement with Persistence Capital Partners II, bearing 12% annual interest and a $25,000 setup fee. The loan, repayable by March 31, 2018, will fund working capital for operations.GlobeNewswireAlliancePharma Announces Transformative AcquisitionsAlliancePharma announced definitive agreements to acquire Pro-J-Pharma, Pharmapar, and liV, plus a $4 million private placement from Persistence Capital Partners. The deals would add over 750 contractors, 1,100 clients, and $50 million in annual gross sales. Closing is subject to conditions, including a new credit facility.FinSMEsmdBriefCase Receives InvestmentmdBriefCase Group, a Toronto-based continuing health education provider, received an undisclosed equity investment from Persistence Capital Partners. The company will use the funds to accelerate expansion into new markets, technologies, and geographies. Founded in 2001, it offers accredited multimedia learning programs for healthcare professionals and patients.BioSpaceWarnex Inc. Comments on Investment by Persistance Capital PartnersPersistence Capital Partners acquired 10,738,750 Warnex shares and $1.5 million in convertible debentures, representing about 16% of the company. SGF Soquia remains a shareholder with approximately 8% of issued shares. The shareholder agreement between Busgang Investments and SGF was terminated.